ICER Value Framework 2020 Update: Recommendations on the Aggregation of Benefits and Contextual Considerations.

Institute for Clinical and Economic Review (ICER) decision conferencing health technology assessement (HTA) healthcare interventions multiple criteria decision analysis (MCDA) quantitative decision analysis value framework

Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818

Informations de publication

Date de publication:
08 2020
Historique:
received: 07 10 2019
revised: 20 04 2020
accepted: 23 04 2020
entrez: 24 8 2020
pubmed: 24 8 2020
medline: 21 10 2020
Statut: ppublish

Résumé

The Institute for Clinical and Economic Review (ICER) in the United States recently published a 2020 update to its value assessment framework. We are commenting on the method by which the benefits of health interventions are integrated, relating to contextual considerations and other factors relevant to an intervention's value. We start by discussing the theoretical foundations of decision analysis and its extension to multiple criteria decision analysis (MCDA). Then we provide a detailed, evidence-based response to some of the claims made by ICER with regard to the use of MCDA methods and stakeholder engagement. Finally, we provide a number of recommendations on the use of quantitative decision analysis and decision conferencing that could be of relevance to the ICER methodology. Overall, we agree that some of the proposed changes by ICER are moving in the right direction toward improving transparency in the value assessment process, but these changes are probably inadequate. We advocate that more serious attention should be paid to the use of quantitative decision analysis together with decision conferencing for the construction of value preferences via group processes for the integration of an intervention's various benefit components.

Identifiants

pubmed: 32828216
pii: S1098-3015(20)32065-9
doi: 10.1016/j.jval.2020.04.1828
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1040-1048

Informations de copyright

Copyright © 2020 ISPOR–The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc. All rights reserved.

Auteurs

Aris Angelis (A)

Department of Health Policy, London School of Economics, London, England, UK. Electronic address: a.n.angelis@lse.ac.uk.

Panos Kanavos (P)

Department of Health Policy, London School of Economics, London, England, UK.

Lawrence D Phillips (LD)

Department of Management, London School of Economics, London, England, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH